India’s antitrust regulator has ordered a probe into Swiss drugmaker Roche for allegedly using anti-competitive practices to restrict cheaper copies of a blockbuster cancer drug from reaching patients.
Summit Therapeutics is about to start pivotal tests of a novel antibiotic discovered by UK scientists to treat a sometimes deadly bowel infection, but Britons could be the last patients to get it after Britain leaves the EU.
Princeton, N.J.-based CRO Covance plans to shutter its lab in Evansville, Ind., in summer 2017. More than 100 staffers are expected to be laid off.
As AstraZeneca continues to move its operations to new headquarters in Cambridge, England, the company quietly pushed back its timeline for a late-stage lung cancer trial.
Novartis reported better-than-expected first-quarter 2017 profits with CEO Joe Jimenez remaining confident the Swiss drugmaker would return to growth in 2018.
Biogen Inc.’s first-quarter 2017 profit blew past analysts’ estimates, helped by higher-than-expected sales of its recently launched spinal muscular atrophy drug Spinraza.
The U.S. Food and Drug Administration posted warning letters addressed to 14 U.S.-based companies illegally selling more than 65 products that fraudulently claim to prevent, diagnose, treat or cure cancer. The products are marketed and sold without FDA approval, most commonly on websites and social media platforms.
Less than 10 days after OncoMed Pharmaceuticals announced its mid-stage combination lung cancer treatment failed to meet endpoints, the company slashed half its workforce in an effort to focus its finances on three clinical-stage programs.
AstraZeneca’s move to the English university city of Cambridge will cost more and take longer than initially expected, following increased expenditure on new technology and equipment.
Germany-based Fresenius Kabi, part of Fresenius SE & Co. KGaA, slapped down $4.3 billion to acquire Illinois-based Akorn Inc. and a larger toehold in the United States.
For many of the healthcare advertising agencies featured within this annual special report, 2016 was another year of growth and change. With the election of Donald Trump as president of the United States and the United Kingdom’s Brexit vote to exit the European Union, the year also introduced uncertainty to agencies and their clients.
To qualify for this annual report, agencies must have the capabilities to develop marketing strategies that target healthcare professionals (physicians, nurse practitioners, nurses, pharmacists, etc.), and/or consumers, and/or patients, and/or stakeholders such as managed market payors.
A listing of holding companies/networks and their healthcare communications agencies and also independent healthcare communications agencies.
2017 Healthcare Agency/Network Industry Person of the Year: Dana Maiman, President and CEO, FCB Health
Recognized as Med Ad News’ 2017 healthcare agency/network industry person of the year, Dana Maiman brings the intellectual prowess and strategic rigor of a legal education to her position as the CEO and president of the FCB Health family of companies worldwide.
On February 22, 2017, a white American man shot two Indian men at Austin’s Bar & Grill in Olathe, Kansas, who he had mistaken as Middle Eastern. The man yelled, “get out of my country” before shooting the men, killing one. A third man was shot and wounded after he came to the mens’ aid. Tragically, the man who was killed, Srinivas Kuchibhotla 32, was the husband of an Intouch Solutions employee, Sunayana Dumala.
While the future of the biopharma and device industries is mostly dependent on what happens in labs and clinical trials, their ability to innovate and successfully market medicines, devices and services operates in a policy soup often flavored by who occupies senior positions in the White House, Congress, the Supreme Court, the Department of Health and Human Services and the Food and Drug Administration.
For AbelsonTaylor, 2016 was a successful year by any measure, according to management. The Cubs won the World Series and the agency grew its client and brand rosters, revenue, staff, and capabilities. Executives say 2015’s growth of more than 16 percent was hard to match, and much of 2016 was spent hiring the staff needed to service new clients and new brands. AbelsonTaylor turned down most pitch opportunities and still grew the business by about 5 percent, according to its leadership, adding that growth came from both new and existing clients and would have been higher had product and project approvals not been pushed into 2017.
Whether engaged in the development of payer market solutions for orphan drugs or in-line medicines, agency leaders say The Access Group remained uniquely positioned in 2016 to support the world’s leading biopharmaceutical companies in maximizing their products’ access to key stakeholders, from patients to physicians to payers.
The U.S. government’s costs could increase by $2.3 billion in 2018 if Congress and President Donald Trump decide not to fund Obamacare-related payments to health insurers, according to a study released by the Kaiser Family Foundation.
How do you top your best year ever? According to Area 23 leaders, you do not try to. After a banner 2015, which saw the agency tack on 35 percent growth, rocket past the $50 million mark, add 65 employees, and rake in more creative awards than any other healthcare agency in the world, Area 23 leaders decided early in 2016 that it would be a year of slow and steady growth, with less pitching and a focus on culture. “Well, the gods of advertising had other plans, and after another explosive year, the agency has broken all of its own growth records once again, expanding another 55 percent in size, and finishing the year with 325 employees and more creative recognition than in any prior year,” executives say.